| Hepatitis C virus： Virology, diagnosis and management of antiviral therapy |
| |
| 引用本文： | Chevaliez S,Pawlotsky JM. Hepatitis C virus： Virology, diagnosis and management of antiviral therapy[J]. World journal of gastroenterology : WJG, 2007, 13(17): 2461-2466. DOI: 10.3748/wjg.v13.i17.2461 |
| |
| 作者姓名： | Chevaliez S Pawlotsky JM |
| |
| 作者单位： | French National Reference Center for Viral Hepatitis B C and delta,Department of Virology & INSERM U841 Henri Mondor Hospital University of Paris XII Créteil France,French National Reference Center for Viral Hepatitis B C and delta,Department of Virology & INSERM U841 Henri Mondor Hospital University of Paris XII Créteil France |
| |
| 摘 要： | Hepatitis C virus (HCV) infects approximately 170 million individuals worldwide. Prevention of HCV infection complications is based on antiviral therapy with the combination of pegylated interferon alfa and ribavirin. The use of serological and virological tests has become essential in the management of HCV infection in order to diagnose infection, guide treatment decisions and assess the virological response to antiviral therapy. Anti- HCV antibody testing and HCV RNA testing are used to diagnose acute and chronic hepatitis C. The HCV genotype should be systematically determined before treatment, as it determines the indication, the duration of treatment, the dose of ribavirin and the virological monitoring procedure. HCV RNA monitoring during therapy is used to tailor treatment duration in HCV genotype 1 infection, and molecular assays are used to assess the end-of-treatment and, most importantly the sustained virological response, i.e. the endpoint of therapy.
|
| 关 键 词： | 丙型肝炎病毒 病毒学 诊断 抗病毒疗法 临床管理 |
| 收稿时间： | 2007-03-07 |
Hepatitis C virus: virology, diagnosis and management of antiviral therapy |
| |
| Chevaliez Stéphane,Pawlotsky Jean-Michel. Hepatitis C virus: virology, diagnosis and management of antiviral therapy[J]. World journal of gastroenterology : WJG, 2007, 13(17): 2461-2466. DOI: 10.3748/wjg.v13.i17.2461 |
| |
| Authors: | Chevaliez Stéphane Pawlotsky Jean-Michel |
| |
| Affiliation: | French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology & INSERM U841, Henri Mondor Hospital, Universityof Paris Ⅻ, Créteil, France |
| |
| Abstract: | Hepatitis C virus (HCV) infects approximately 170 million individuals worldwide. Prevention of HCV infection complications is based on antiviral therapy with the combination of pegylated interferon alfa and ribavirin. The use of serological and virological tests has become essential in the management of HCV infection in order to diagnose infection, guide treatment decisions and assess the virological response to antiviral therapy. Anti- HCV antibody testing and HCV RNA testing are used to diagnose acute and chronic hepatitis C. The HCV genotype should be systematically determined before treatment, as it determines the indication, the duration of treatment, the dose of ribavirin and the virological monitoring procedure. HCV RNA monitoring during therapy is used to tailor treatment duration in HCV genotype 1 infection, and molecular assays are used to assess the end-of-treatment and, most importantly the sustained virological response, i.e. the endpoint of therapy. |
| |
| Keywords: | Hepatitis C virus serological tests Hepatitis C virus genotype HCV RNA quantification Interferon alpha Ribavirin |
| 本文献已被 CNKI 维普 万方数据 PubMed 等数据库收录！ |
|
